What is it about?
This exhaustive literature review (1980–2025) highlights the phytochemistry, structural diversity, and therapeutic potential of alkamides derived from major Asteraceae genera—such as Artemisia, Echinacea, Acmella, Anacyclus, Heliopsis, Wedelia, and Spilanthes—which yield olefinic, polyunsaturated, acetylenic, and saturated classes. Mechanistically, these bioactive compounds exhibit significant anti-inflammatory (via TNF-$\alpha$ inhibition), apoptotic anticancer, neuroprotective, antioxidant, and TRPV1-mediated analgesic properties. Crucially, due to their structural similarity to the endocannabinoid anandamide, Asteraceae alkamides interact effectively with CB2 receptors, positioning them as promising lead candidates for developing non-psychoactive cannabinoid-inspired analgesics, immunomodulators, and anti-inflammatory drugs; however, further research on their pharmacokinetics, structure-activity relationships, biosynthesis pathways, and safety profiles remains essential to advance their clinical drug development.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Why is it important?
This study is important because it represents the first comprehensive, long-term systematic review (1980–2025) mapping the phytochemistry, distribution, and biological activities of alkamides across key Asteraceae genera (Artemisia, Echinacea, Acmella, Anacyclus, Heliopsis, Wedelia, and Spilanthes). By demonstrating that these alkamides exhibit structural similarities to the endocannabinoid anandamide and selectively target CB2 receptors, the study establishes a crucial scientific foundation for developing non-psychoactive, cannabinoid-inspired therapeutics. Furthermore, by detailing their structure-activity relationships and diverse pharmacological mechanisms—including TNF-$\alpha$ inhibition for anti-inflammation, TRPV1 modulation for pain relief, apoptosis induction for cancer, and neuroprotection—this work provides medicinal chemists and pharmacologists with a strategic roadmap to optimize lead compounds for clinical drug discovery while identifying key gaps in pharmacokinetic and safety profiles.
Perspectives
The perspectives of this study lie in translating 45 years (1980–2025) of phytochemical, structural, and mechanistic data on Asteraceae alkamides into actionable leads for non-psychoactive, cannabinoid-inspired drug development. By demonstrating how specific alkamide classes (such as spilanthol, affinin, and polyene isobutylamides) mimic endocannabinoids to target CB2 receptors, modulate TRPV1 channels, and inhibit pro-inflammatory cytokines like TNF-$\alpha$, the review establishes a clear framework for optimizing structure-activity relationships to engineer novel analgesics, anti-inflammatory agents, immunomodulators, and supportive cancer therapeutics. To successfully bridge these promising natural compounds into clinical practice, future research must prioritize elucidating their biosynthetic pathways, resolving pharmacokinetic challenges (such as absorption, metabolism, and bioavailability), and conducting comprehensive toxicity and clinical safety evaluations.
Dr Mayssaloune Ali Kanso
Beirut Arab University
Read the Original
This page is a summary of: Alkamides in Asteraceae Family: Bioactivity and Structural Relationships, Current Bioactive Compounds, May 2026, Bentham Science Publishers,
DOI: 10.2174/0115734072440189260508144100.
You can read the full text:
Contributors
The following have contributed to this page
